Treatment for Few Metastases | Oligo-Metastases Disease | Mark Scholz, MD | PCRI

Treatment for Few Metastases | Oligo-Metastases Disease | Mark Scholz, MD | PCRI

Advanced #ProstateCancer Treatments + Extended Q+A | #MarkScholzMD & #MarkMoyadMD #PCRISee more

Advanced #ProstateCancer Treatments + Extended Q+A | #MarkScholzMD & #MarkMoyadMD #PCRI

Testosterone Replacement Therapy For Metastatic #ProstateCancer | #MarkScholzMD #AlexScholz #PCRISee more

Testosterone Replacement Therapy For Metastatic #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI

Radiation and Hormone Therapy | Prostate Cancer | Mark Scholz, MD | PCRISee more

Radiation and Hormone Therapy | Prostate Cancer | Mark Scholz, MD | PCRI

Gleason 9 & 10 Prostate Cancer: Cure Rates, Treatments, New Approaches | Mark Scholz, MD | PCRISee more

Gleason 9 & 10 Prostate Cancer: Cure Rates, Treatments, New Approaches | Mark Scholz, MD | PCRI

Treating Lymph Node Metastases #ProstateCancer | #MarkScholzMD | #AlexScholz #PCRISee more

Treating Lymph Node Metastases #ProstateCancer | #MarkScholzMD | #AlexScholz #PCRI

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRISee more

New FDA Approval: Darolutamide for Hormone-Sensitive Disease | Mark Scholz, MD | PCRI

How Does #ProstateCancer Spread to the Bones? | Spot & Injectable Radiation | #MarkScholzMDSee more

How Does #ProstateCancer Spread to the Bones? | Spot & Injectable Radiation | #MarkScholzMD

The Pros and Cons of Proton Therapy | Mark Scholz, MD | PCRISee more

The Pros and Cons of Proton Therapy | Mark Scholz, MD | PCRI

Metastatic #ProstateCancer Treatment Case Study | #MarkScholzMD #AlexScholz #PCRISee more

Metastatic #ProstateCancer Treatment Case Study | #MarkScholzMD #AlexScholz #PCRI

Bone Metastasis: Diagnosis and Scans | #MarkScholzMD #AlexScholz #PCRISee more

Bone Metastasis: Diagnosis and Scans | #MarkScholzMD #AlexScholz #PCRI

Salvage Radiation, Lutetium-177, 3+4=7, & What is Cribriform? | Mark Scholz, MD | PCRISee more

Salvage Radiation, Lutetium-177, 3+4=7, & What is Cribriform? | Mark Scholz, MD | PCRI

Treating Non-Metastatic Castrate Resistant Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MDSee more

Treating Non-Metastatic Castrate Resistant Prostate Cancer | Ask a Prostate Expert, Mark Scholz, MD

New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRISee more

New FDA Approved: Pluvicto (Lutetium-177) for Advanced Prostate Cancer | Mark Scholz, MD | PCRI

Xofigo | How It Works, Side Effects, and More | Ask a Prostate Expert, Mark Scholz, MD | PCRISee more

Xofigo | How It Works, Side Effects, and More | Ask a Prostate Expert, Mark Scholz, MD | PCRI

Prostate Cancer Mortality Rate Explained | Answering YouTube Comments #48 | Mark Scholz, MD | PCRISee more

Prostate Cancer Mortality Rate Explained | Answering YouTube Comments #48 | Mark Scholz, MD | PCRI

Radiation, PSMA, Immune Therapy | Questions From The PCRI Mid-Year Update | Mark Scholz, MDSee more

Radiation, PSMA, Immune Therapy | Questions From The PCRI Mid-Year Update | Mark Scholz, MD

Finding an Oncologist for Advanced Disease | Scanning for Metastases Early | Mark Scholz, MD | PCRISee more

Finding an Oncologist for Advanced Disease | Scanning for Metastases Early | Mark Scholz, MD | PCRI

Bone Metastasis: Treatments, Scans & Side Effects | Ask a Prostate Expert, Mark Scholz, MDSee more

Bone Metastasis: Treatments, Scans & Side Effects | Ask a Prostate Expert, Mark Scholz, MD

Remission and Cure After Relapse Prostate Cancer | Mark Scholz, MD | PCRISee more

Remission and Cure After Relapse Prostate Cancer | Mark Scholz, MD | PCRI

Actual